INBX

Inhibrx Biosciences Inc

• Simply Wall St·8h ago

  How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story

• Simply Wall St·5d ago

  A Look At Inhibrx Biosciences (INBX) Valuation After HexAgon Phase 2 Data And Phase 3 Plans

• TipRanks·05/16 14:35

  LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)

• TipRanks·05/15 13:15

  Inhibrx price target raised to $325 from $300 at Stifel

• TipRanks·05/15 12:45

  Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

• Reuters·05/15 11:43

  INHIBRX BIOSCIENCES INC <INBX.O>: STIFEL RAISES TARGET PRICE TO $325 FROM $300

• TipRanks·05/14 21:48

  Inhibrx reports Q1 EPS ($2.15) vs. ($2.80) last year

• Seeking Alpha·05/14 20:46

  Inhibrx Biosciences GAAP EPS of -$2.15

• Reuters·05/14 20:09

  Inhibrx Q1 net loss narrows as R&D costs fall

• Simply Wall St·05/12 00:33

  Should Positive INBRX-106 Phase 2 Combo Data in Head and Neck Cancer Require Action From Inhibrx Biosciences (INBX) Investors?

• TipRanks·05/11 21:13

  Inhibrx Biosciences Reports Positive Interim Phase 2 Results

• TipRanks·05/11 16:20

  Inhibrx’s INBRX-106 shows potential benefit in HNSCC

• TipRanks·05/11 14:10

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)

• PUBT·05/11 12:03

  Inhibrx says INBRX-106 plus pembrolizumab lifts Phase 2 HNSCC response rate to 44%

• Reuters·05/11 12:00

  INHIBRX BIOSCIENCES INC - INBRX-106 PLUS PEMBROLIZUMAB ACHIEVES 44.0% CONFIRMED ORR VS 21.4% WITH PEMBROLIZUMAB ALONE